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Abstract
Background: Primary hepatocytes are the best resource for in vitro studies directed at understanding hepatic
processes at the cellular and molecular levels, necessary for novel drug development to treat highly prevalent
diseases such as non-alcoholic steatohepatitis, cardiovascular disease and type 2 diabetes. There is a need to
identify simple methods to genetically manipulate primary hepatocytes and conduct functional studies with
plasmids, small interfering RNA (siRNA) or microRNA (miRNA). New lipofection reagents are available that have the
potential to yield higher levels of transfection with reduced toxicity.
Findings: We have tested several liposome-based transfection reagents used in molecular biology research. We
show that transfection efficiency with one of the most recently developed formulations, Metafectene Pro, is high
with plasmid DNA (>45% cells) as well as double stranded RNA (>90% with siRNA or microRNA). In addition,
negligible cytotoxicity was present with all of these nucleic acids, even if cells were incubated with the DNA:lipid
complex for 16 hours. To provide the proof of concept that these conditions can be used not only for
overexpression of a gene of interest, but also in RNA interference applications, we targeted two liver expressed
genes, Sterol Regulatory Element-Binding Protein-1 and Fatty Acid Binding Protein 5 using plasmid-mediated short
hairpin RNA expression. In addition, similar transfection conditions were used to optimally deliver siRNA and
microRNA.
Conclusions: We have identified a lipid-based reagent for primary hepatocyte transfection of nucleic acids
currently used in molecular biology laboratories. The conditions described here can be used to expedite a large
variety of research applications, from gene function studies to microRNA target identification.
Background
The liver is a critical tissue that controls carbohydrate
and lipid homeostasis. Highly prevalent human condi-
tions, including obesity, cardiovascular disease, the
metabolic syndrome, non-alcoholic steatohepatitis
(NASH), or type 2 diabetes, are characterized by altera-
tions in hepatic glucose and/or lipid metabolism. Deci-
phering the molecular mechanisms that mediate
metabolic responses will open the possibility for the
development of more effective therapies.
Establishing the function of genes and/or validating
their role in disease is commonly attained through
generation of null alleles. The discovery of RNA inter-
ference (RNAi) has provided novel avenues to accelerate
g e n ef u n c t i o ns t u d i e sa sw e l la sd r u gt a r g e td i s c o v e r y
[1-5]. RNAi is triggered by double stranded
RNA (dsRNA) of variable lengths, typically 21 to 28-
nucleotides (nt). These can be chemically synthesized
molecules (known as small interfering RNA, or siRNA)
that upon delivery into cells or tissues, block gene
expression for a few days. Re-administration is necessary
for a sustained silencing effect. Alternatively, short hair-
pin RNA (shRNA) can be used to provide a continuous
source of silencing molecules. To generate shRNA,
expression cassettes are engineered using RNA polymer-
ase II or RNA polymerase III promoters. The shRNA is
transcribed in the nucleus as a linear molecule that
folds to generate a stem of approximately 21-nt,
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shRNA hairpin structure is cleaved into a siRNA [6-8].
Once an effective silencing shRNA construct is identi-
fied, the expression cassette can be incorporated into
viral vectors for delivery to tissues in vivo [9].
In recent years it has become clear that microRNA
(miRNA) are crucial modulators of biological functions,
affecting processes as important as development and cell
cycle stage. It has been estimated that more than 30% of
human genes are regulated by miRNA at an average of
200 genes per miRNA [10-13]. MicroRNA exert their
action by binding to the 3’ UTR of mRNA and inhibit-
ing protein synthesis or inducing mRNA degradation
[14,15]. Gene target prediction coupled to experimental
confirmation is beginning to yield information on the
role of miRNA in normal cellular pathways as well as in
disease. MicroRNA target identification is typically
attained by transfection using chemically synthesized
miRNA mimics (acting as mature miRNA that decrease
levels of target mRNA and/or protein).
The primary culture of hepatocytes is regarded as the
cellular model with highest similarity to liver physiology,
and is the preferred approach to perform functional stu-
dies. Primary hepatocytes can be easily obtained by
enzymatic digestion with collagenase [16-18]. Compared
to other methods, transfection with cationic lipids offers
the advantage of being a simple method of gene transfer,
shortening gene function studies considerably. In recent
years a variety of novel lipofection reagents have been
developed with the potential to improve nucleic acid
delivery in the absence of toxic effects. Optimization
experiments in primary cells are highly time-consuming
and expensive to perform. Here, we show transfection
conditions with DNA and RNA molecules to knock-
down two hepatic genes, Sterol Regulatory Element-
Binding Protein-1 (SREBP-1) and Fatty Acid Binding
Protein 5 (FABP5), using shRNA-expressing plasmids or
siRNA. Similar conditions were successfully used to
transfect primary hepatocytes with miRNA.
Results and discussion
Plasmid transfection optimization
Critical aspects of mouse primary hepatocyte isolation
by collagenase digestion are the strain and age of the
animal, which affect cell viability, even if using the same
collagenase concentration and perfusion time (data not
shown). Using the protocol described in the Methods
section, we consistently obtained high cell yield and via-
bility (85-90%). High transfection efficiency can be
obtained in cell lines with essentially all commercial
transfection reagents, whereas primary cells in general
have proven much more difficult to transfect [19,20].
Plasmid transfection, in particular, is more challenging,
as these are large molecules and more difficult to be
taken up by cells. To analyze the potential of novel lipo-
fection methods to improve primary hepatocyte gene
delivery, a 3 kb plasmid expressing green fluorescent
protein (GFP) was complexed to four reagents: Metafec-
tene, Metafectene Pro, Lipofectamine 2000, and
Targefect-Hepatocyte. These reagents were selected
based on information available from the respective com-
pany indicating high transfection efficiency in multiple
cell lines and/or primary cells (including primary hepa-
tocytes), in addition to low toxicity. To develop an opti-
mal protocol for transfecting plasmid DNA into primary
hepatocytes, DNA:lipid ratio, DNA concentration, cul-
ture medium and transfection time were considered. As
shown in Figure 1A, we found that transfection was
most efficient with all reagents when using a DNA:lipid
ratio of 1:4. Targefect yielded the highest transfection
efficiency (45.8 ± 4.2%), followed by Metafectene Pro
(40.3 ± 2.6%), Lipofectamine 2000 (37.3 ± 3.8%), and
Metafectene (31.5 ± 2.9%) (Figure 1A). We then tested
the effect of total amount of DNA, by transfecting cells
with 1 to 5 μg, and maintaining the 1:4 (DNA:lipid)
ratio. The highest transfection efficiency in the absence
Figure 1 Effect of DNA:lipid ratio and DNA concentration on
transfection efficiency. Cells were transfected with pRNAT-H1.1/
neo GFP plasmid complexed with Metafectene (Met), Metafectene
Pro (Met Pro), Lipofectamine 2000 (Lipo 2000) or Targefect (Targe),
for 16 hr. (A) DNA:lipid ratio. Two μg DNA was complexed with lipid
at ratios of 1:0.5, 1:1, 1:2, 1:4, 1:8, 1:16. The percentage of GFP-
positive cells was determined 24 hr after transfection. Values
represent the average of 4 independent experiments. (B) DNA
concentration. Using a 1:4 DNA:lipid ratio, cells were transfected
with 1, 2, 3, 4, and 5 μg of DNA. The percentage of GFP-positive
cells was determined 24 hr after transfection. Values represent the
average of 3 independent experiments.
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ure 1B). Because Metafectene gave the lowest transfec-
tion efficiency under all conditions, further optimization
experiments were conducted without this reagent.
To investigate the influence of medium and transfec-
tion time, primary hepatocytes were transfected with
Metafecte Pro, Lipofectamine 2000 or Targefect in the
presence of DMEM (Figure2 A )o rO p t i - M E M ,w i t h /
without Virofect enhancer, for 3 hours or 16 hours (Fig-
ure 2A, 2B, 2C). The presence of Opti-MEM resulted in
significantly higher transfection rates when Lipofecta-
mine 2000 was used (approximately 10% increase at
both, 3 and 16 hours) (Figure 2B, 2C), a small but sig-
nificant increase on cells incubated with Targefect for
3 hours (Figure 2B), and no statistically significant dif-
ference with Metafectene Pro (Figure 2B, 2C). Virofect
enhancer had no significant effect on transfection effi-
ciency when Metafectene Pro, Lipofectamine 2000 or
Targefect were used (Figure 2B, 2C). Interestingly,
longer transfection time had a large influence on per-
centage of GFP-positive cells when Targefect was used.
For example, in DMEM-incubated cells, 5.8 ± 1.6% were
GFP-positive when transfection lasted 3 hours, while
50.6 ± 1.9% were positive when cells were transfected
for 16 hours (p < 0.01). Transfection time also influ-
enced the % of GFP-positive cells when using Lipofecta-
mine 2000. Approximately a 10% increase was observed
at 16 hours compared to 3 hours (31.4 ± 2.3% at
3 hours and 41.6 ± 2.5% at 16 hours with DMEM; p <
0.01; 38.6 ± 1.1% at 3 hours and 51.2 ± 2.4% at 16
hours with Opti-MEM; p < 0.01). Transfection time had
a negligible effect with Metafectene Pro (39.8 ± 2.2% at
3 hours and 43.0 ± 2.1% at 16 hours, using DMEM; p =
0.046; 40.4 ± 1.8% at 3 hours and 42.8 ± 1.9% at 16
hours using Opti-MEM; p = 0.07).
High efficiency of transfection is often associated with
toxicity. Ideally, a transfection reagent should yield high
transfection efficiency with minimal or no cytotoxicity.
To examine this, primary hepatocytes were cultured in
t h ep r e s e n c eo fD M E Mo rO p t i - M E M ,u s i n gM e t a f e c -
tene Pro, Lipofectamine 2000, and Targefect and cyto-
toxicity was evaluated after 24, 48, and 72 hr. As shown
in Table 1, there was barely any difference in cytotoxi-
city among transfection reagents at 24 hours post-
transfection; however Metafectene Pro resulted in much
less cytotoxicity than Lipofectamine 2000 and Targefect
at 48 and 72 hours post-transfection. Targefect yielded
the highest level of transfection, but was by far the most
Figure 2 Influence of culture medium and incubation time on
transfection efficiency. Primary hepatocytes were transfected with
2 μg of plasmid and Metafectene Pro (Met Pro), Lipofectamine 2000
(Lipo 2000) and Targefect (Targe) at a ratio of 1:4. Cells were
incubated with DMEM or Opti-MEM for 3 hr or 16 hr. The
percentage of GFP-positive cells was determined 24 hr after
transfection. (A) GFP images were taken from cells incubated with
DMEM media. (B) Quantification of GFP-positive cells after 3 hr
transfection in the presence of DMEM or OptiMEM with or without
Virofect enhancer. (C) Quantification of GFP-positive cells after 16 hr
transfection in the presence of DMEM or OptiMEM with or without
Virofect enhancer. Values represent the average of 5 independent
experiments. *p < 0.01, **p < 0.05 between DMEM and Opti-MEM,
and DMEM/Viro and Opti-MEM/Viro.
Table 1 Cytotoxic effect induced by transfection reagents
Reagents Media Cytotoxicity
24 hr 48 hr 72 hr
Negative control DMEM - - -
Opti-MEM - - -
Metafectene Pro DMEM - + +
Opti-MEM - + +
Lipofectamine 2000 DMEM - ++ +++
Opti-MEM - + ++
Targefect DMEM + +++ ++++
Opti-MEM - ++ ++++
Cytotoxicity was assessed by estimating the percentage of cell density in 6
fields per well, relative to the negative control for each time point. +: < 20%;
++: < 40%; +++: < 60%; ++++: < 80% cell death.
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slightly higher levels of transfection than Metafectene
Pro and similar levels of toxicity when cells were cul-
tured in the presence of Opti-MEM. However, transfec-
tion using Lipofectamine 2000 resulted in lower
reproducibility than the other reagents, which was
affected by elapsed time between cell plating and trans-
fection (data not shown). Overall, Metafectene Pro gave
the most consistent results, with least toxicity and short-
est transfection time. This reagent has been previously
shown to have superior performance in prostate cancer
cells and the human embryonic carcinoma (EC) stem
cell line NTERA2 [21]. Our data suggest that Metafec-
tene Pro is a suitable reagent for use in primary hepato-
cytes, either for short-term expression (< 24 hours) or
longer expression (>24 hours).
SREBP-1 and FABP5 silencing in primary hepatocytes
To provide the proof of concept that the transfection
conditions described above are sufficient to silence an
endogenous gene, primary hepatocytes were transfected
with plasmids expressing shRNA to knock-down the
transcription factor SREBP-1 [9] and the fatty acid bind-
ing protein FABP5 [22]. As shown in Figure 3, SREBP-1
mRNA expression was significantly reduced to 58% and
18% (at 24 and 48 hours, respectively) compared to the
levels observed in cells treated with the shSCR control
plasmid [expressing a scrambled sequence that does not
bind to an mRNA, based on Basic Local Alignment
Search Tool (BLAST) analysis (National Center for Bio-
technology Information, NIH]. Western blot analysis
revealed that SREBP-1 protein levels decreased in paral-
lel to mRNA levels. FABP5 mRNA was reduced to 44%
and 12% at 24 and 48 hours, respectively, compared to
samples treated with shSCR plasmid. FABP5 protein
reduction was evident only in samples harvested
48 hours after transfection, suggesting this protein has a
long half-life. Thus, when testing the efficacy of custom-
designed shRNA sequences, measuring the mRNA of
the target gene is a more reliable method to assess the
silencing efficacy of the constructs than measuring pro-
tein levels. In conclusion, the conditions reported here
allow gene silencing of two independent genes by trans-
fection of plasmids expressing shRNA.
When conducting studies to address the function of a
gene, using a chemically synthesized siRNA may be the
preferred approach. In these experiments as well as in
experiments directed at miRNA target identification, it
is important to use conditions that result in highest
transduction efficiency, to maximize the level of inhibi-
tion on mRNA and/or protein expression. To optimize
the transfection conditions using a chemically synthe-
sized double stranded RNA molecule, a fluorescently
labeled miRNA, was used. Cells were transfected with
0.5, 1, or 2.5 μg of Dy547-labeled miRIDIAN microRNA
Mimic Transfection Control. All conditions resulted in
the presence of a fluorescent signal in the cytoplasm in
a high percentage of cells (>90%). Using 2.5 μgo f
miRNA the intensity in the cytoplasm was slightly
stronger than in cells transfected with 1 μg, but there
were large clumps outside of the cells, suggesting that
not all nucleic acid was taken by cells. Experiments
were repeated in 6-cm dishes using the same dsRNA:
lipid ratio and 1.5, 3.0 and 4.5 μg miRNA. Similar
results were observed to those seen in 6-well plates (Fig-
ure 4A). No cytotoxicity was observed in any of these
conditions for 48 hours.
To test the feasibility of using these conditions for
transfection using siRNA, primary hepatocytes were
incubated with siRNA to target FABP5, a non-targeting
siRNA or with FABP1 siRNA (another member of the
FABP family expressed in liver) (Figure 4B). A signifi-
cant FABP5 knock-down was observed after 72 and
96 hours with the siRNA specific to FABP5. Thus, similar
transfection conditions can be used for delivery of large
plasmids, miRNA and siRNA in primary hepatocytes.
In addition to be important for gene function studies,
plasmid-mediated expression of shRNA in primary
hepatocytes has other applications. In vivo RNAi offers
the possibility to overcome many of the limitations pre-
sented by knock-out animal models. For example,
absence of a gene may be incompatible with develop-
ment, leading to death in utero. Using viral vector deliv-
ery of shRNA-expression cassettes it is possible to
induce gene silencing in an adult animal. For the liver,
in particular, adenovirus-mediated shRNA expression
represents an excellent alternative, as the adenovirus has
high tropism for hepatocytes [9]. Using the approach
described here, several shRNA-expressing plasmids can
be tested for their efficacy at silencing the target gene in
primary hepatocytes, prior to transferring the most effi-
cient shRNA expression cassette to an adenoviral vector
for in vivo studies.
Conclusion
This study shows efficient transfection of primary hepa-
tocytes and negligible cytotoxicity using plasmid DNA
and dsRNA complexed to Metafectene Pro. These con-
ditions can be applied to (i) functional studies where a
gene of interest needs to be silenced, (ii) gene overex-
pression studies, (iii) testing the efficacy of shRNA con-
structs to target hepatic genes, and (iv) delivery of small
RNA molecules, such as siRNA or miRNA mimics,
which resulted in >90% transfection efficiency. The pri-
mary hepatocyte transfection conditions described here
can be used to accelerate gene discovery, drug target
validation and miRNA target identification studies, that
are urgently needed to treat prevalent human diseases
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Figure 3 Gene silencing using plasmid transfection. Primary hepatocytes cultured in DMEM were transfected with plasmids (2 μg) expressing
shRNA to knock-down SREBP1 or FABP5 and Metafectene Pro (1:4 ratio), for 16 hr. (A) SREBP-1 gene silencing; (B) FABP5 gene silencing. The
level of mRNA was quantified by real-time RT-PCR (A and B, top). The level of silencing is expressed relative to medium-treated cells. Proteins
were quantified by Western blot (A and B, bottom). b-actin was used as a normalizer. Data are representative of two independent experiments
(n = 3); *p < 0.05; **p < 0.01 shSCR compared to shSREBP-1 or shFABP5.
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cular disease, and type 2 diabetes.
Materials and methods
Animals
Male C57BL/6J mice (11 to 12 wks old, 26 to 30 g) were
purchased from The Jackson Laboratory (Bar Harbor,
ME). Mice were fed rodent chow ad libitum and
allowed free access of water. A standard 12 h light/12 h
dark cycle (7 AM/7 PM) was maintained throughout the
experiments. Animal studies were performed in compli-
ance with Indiana University School of Medicine Institu-
tional Animal Care and Use Committee guidelines.
Isolation of mouse primary hepatocytes
Primary hepatocytes were isolated by collagenase diges-
tion, following a previously described protocol [16,17].
Mice were anesthetized by intraperitoneal injection of
sodium pentobarbital (90 mg/kg). The portal vein was
cannulated with a 22-gauge intravenous catheter. The
liver was perfused with Ca
2+,M g
2+-free Hanks’ buffer
solution (Invitrogen, Carlsbad, CA) containing 0.5 mM
ethylene glycol-bis-(2-aminoethylether) N,N,N’,N’-tetra-
cetic acid (EGTA), and 0.05 M N-2-hydroxyethylpipera-
zine-N-2-ethane sulfonic acid (HEPES) (pH 7.4)
maintained at 37°C, at a rate of 5 ml/min for 5 min.
This was followed by perfusion of the collagenase-con-
taining solution [DMEM (Cellgro, Lawrence, KS) with
0.05% collagenase Type IA (Sigma, St. Louis, MO)] for
5 minutes (5 ml/min), with intermittent obstruction of
the inferior vena cava for 15 seconds. The liver was trans-
ferred to 10 mm dishes with 15 ml DMEM containing
0.05% collagenase and was mechanically dissociated into
single cells. Ten ml DMEM supplemented with 10%
heat-inactivated fetal bovine serum (FBS) were added to
cells to reduce collagenase activity. Cells were filtered
through a 70 μmp o r es i z es t r a i n e r( B D ,S a nJ o s e ,C A )
and centrifuged at 100 × g for 5 min at 10°C. The cell
pellets were gently washed with 20 ml DMEM/10% FBS,
and centrifuged at 100 × g for 5 min at 10°C. This low
centrifugation step allows pelleting hepatocytes while sig-
nificantly reducing the number of other smaller liver cells
[17]. Cells were resuspended in DMEM/10% FBS with
antibiotics. Cell viability was assessed by trypan blue dye
exclusion (85-90%). Primary hepatocytes were plated at a
d e n s i t yo f4×1 0
5 cells in 2 ml of DMEM/10% FBS with
antibiotics on 6-well plates, which resulted in 90% con-
fluency the day after (Corning, Lowell, MA). Medium
was replaced 2 hours after plating.
Transient transfection
After overnight incubation, plated primary hepatocytes
were transfected with plasmid pRNAT-H1.1/neo con-
taining a green fluorescent protein (GFP) expression
cassette (GeneScript, Piscataway, NJ). Four transfection
reagents were tested: Metafectene (Biontex Laboratories
GmbH, Munich, Germany), Metafectene Pro (Biontex
Laboratories GmbH), Lipofectamine 2000 (Invitrogen)
and Targefect-Hepatocyte (Targeting Systems, El Cajon,
CA). Given that each manufacturer recommends differ-
ent time frames for incubation of cells with DNA/lipid
complexes, 3 and 16 hours were used, as these covered
the lowest and highest times suggested. DNA and lipid
were diluted in 100 μl of medium (in the absence of
FBS and antibiotics), in separate tubes. DNA was added
to the lipid, gently mixed, and incubated at room tem-
perature for 20 minutes. The complex was added to the
cells and the plate was carefully swirled to ensure even
distribution. Transfection was conducted in the presence
of Dulbecco’s modified Eagle’sm e d i u m( D M E M )o r
OptiMEM supplemented with 10% FBS, 100 U of peni-
cillin G and 100 μg of streptomycin per ml. In addition,
some experiments (as described in the text) included
Virofect in the transfection medium. Cells were incu-
bated at 37°C in a 5% CO2 incubator. Medium was
replaced with DMEM or OptiMEM containing 10% FBS
and antibiotics after 3 or 16 hours of transfection. All
conditions were tested in duplicate wells and at least in
three independent experiments. GFP-positive cells were
counted in 6 fields per well on an inverted microscope
CKX41 (Olympus, Center Valley, PA) with fluorescence
illuminator, BH2-RFL-T3 (Olympus). Fluorescence
images were acquired with a Nikon TE 2000 U inverted
Figure 4 miRNA and siRNA transfection. (A) miRNA transfection.
Primary hepatocytes were cultured in 6-cm dishes at 1 × 10
6 cell/
dish and transfected with 1.5, 3.0 and 4.5 μg Dy547-labeled
miRIDIAN microRNA Mimic Transfection Control. The percentage of
positive cells was determined 24 hr after transfection. (B) siRNA
transfection to knock-down FABP5. Cells were cultured in 6-well
plates and incubated with 2 μg FABP5 siRNA, FABP1 siRNA or non-
targeting siRNA (ratio 1:3). Cells were harvested 72 or 96 hours later.
FABP5 levels were analyzed by Western blot. FABP1 is a member of
the FABP family. Only the siRNA that is specific for FABP5 reduces
its protein levels. siNT, non-targeting siRNA; siF1, FABP1 siRNA; siF5,
FABP5 siRNA.
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WD Plan Fluor 0.60NA DIC objective (Melville, NY), a
Hamamatsu 1394 Orca-ER Cooled CCD Camera
(Bridgewater, NJ). Images were processed with Image J
software (NIH, Bethesda, MA).
Cytotoxicity was assessed by estimating the percentage
of cell density in 6 fields per well, relative to the nega-
tive control for each time point (+: < 20%; ++: < 40%;
+++: < 60%; ++++: < 80% cell death).
The construction of shRNA-expressing plasmids to
knock-down SREBP-1 and FABP5 has been previously
described [9,22]. For microRNA transfection optimiza-
tion in 6-well plates, 0.5, 1, or 2.5 μg of Dy547-labeled
miRIDIAN microRNA Mimic Transfection Control
(Dharmacon, Lafayette, CO) was mixed with Metafec-
tene Pro at a 1:3 ratio, fol l o w i n gt h es a m ep r o t o c o l
described above for plasmids. The experiments were
scaled-up to 6-cm dishes using 1 × 10
6 cells and 1.5, 3.0
and 4.5 μg miRNA. For FABP5 silencing using siRNA,
siGenome SMARTpool siRNA (Dharmacon) were used
following the conditions described in the text.
qRT-PCR analysis
Total RNA was isolated using Qiagen (Valencia, CA)
RNeasy kit following the manufacturer’s protocol. qRT-
PCR was used to quantify mRNA levels of SREBP-1,
FABP5 and b-actin using primer pairs: SREBP-1, 5’-
TGCTTTGGAACCTCATCCGC-3’ and 5’-AGCAGCAA-
GATGTCCTCCTGT-3’;F A B P 5 ,5 ’-CCATGGCCAGCCT-
TAAGGA-3’ and 5’-ACCTTCTCATAGACCCGAGT-3’;
b-actin, 5’-CTACAATGAGCTGCGTGTGGC-3’ and 5’-
ATGGCTGGGGTGTTGAAGGTC-3’.q R T - P C Rw a sp e r -
formed using an ABI PRISM 7500 instrument (ABI, Foster
City, CA) and SYBR Green Qiagen One-Step reverse tran-
scription-PCR kit (Qiagen, Valencia, CA), following the
manufacturer’s recommendations. Quantification of
mRNA levels was done by analyzing 50 ng of total RNA,
in duplicate and comparing Ct values with those of the
standard curve. The b-actin gene was used as loading con-
trol. Fold changes are expressed relative to the shSCR-
transfected group.
Western blot
Transfected primary hepatocytes were lysed in modified
RIPA buffer containing protease inhibitors, as previously
described [22]. Protein concentration was determined
using the BCA kit from Pierce (Rockford, IL). Proteins
(20-40 μg) were separated in 4-20% SDS-polyacrylamide
Criterion gels (Bio-Rad, Hercules, CA) and transferred
to polyvinylidene difluoride (PVDF) membranes
(Bio-Rad). Primary antibodies were used at the following
concentrations in overnight incubations at 4°C:
SREBP-1, 1:400; FABP5, 1:500; b-actin, 1:500). Second-
ary antibody was added and incubated at room
temperature for 1 hour at the following dilutions: HRP-
conjugated anti-rabbit IgG, 1:3,000; anti-goat IgG,
1:3,000. The anti-SREBP-1 and b-actin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The anti-FABP5 and all secondary antibodies were
purchased from R&D Systems (Minneapolis, MN). Blots
were developed with Immun-Star (Bio-Rad) and exposed
to ECL film (GE Healthcare).
Statistical analysis
All experimental conditions were done in duplicate and
repeated in at least two separate hepatocyte isolations.
Data are presented as the arithmetic mean ± standard
deviation. Statistical differences were calculated with a
two-tailed, unpaired Student’s t-test. Data were consid-
ered significant at p < 0.05.
Abbreviations
siRNA: small interfering RNA; shRNA: short hairpin RNA; miRNA: microRNA;
RNAi: RNA interference; FABP5: Fatty Acid Binding Protein 5; SREBP-1: Sterol
Regulatory Element-Binding Protein-1.
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